Oncology & Cancer

High response seen for chemo in seniors with high-risk AML

(HealthDay)—A substantial proportion of older patients with high-risk acute myeloid leukemia (AML) treated with chemotherapy are long-term survivors, according to research published online June 7 in Cancer Medicine.

Oncology & Cancer

Allo-HCT with unrelated donor tied to better outcomes in AML

(HealthDay)—Allogeneic hematopoietic cell transplantation (allo-HCT) with an unrelated donor (UD) results in better transplantation outcomes than cord blood transplantation (CBT) in acute myeloid leukemia (AML) patients ...

Oncology & Cancer

Octogenarians with acute myeloid leukemia have poor survival

(HealthDay)—Octogenarians with acute myeloid leukemia (AML) have a one-month mortality rate of 41 percent and overall survival (OS) of 1.5 months, according to a research letter published in the June issue of the American ...

Oncology & Cancer

Presence of leukemia cutis tied to worse survival in AML

(HealthDay)—For patients with acute myeloid leukemia (AML), the presence of leukemia cutis (LC) is associated with decreased overall and leukemia-specific survival, according to a study published online April 10 in JAMA ...

Oncology & Cancer

Population mortality affects long-term follow-up of AlloHCT

(HealthDay)—For older patients undergoing allogeneic hematopoietic cell transplantation (alloHCT), a considerable part of total nonrelapse mortality (NRM) is attributable to population mortality, according to a study recently ...

page 1 from 23

Acute myeloid leukemia (AML), also known as acute myelogenous leukemia, is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting for approximately 1.2% of cancer deaths in the United States, its incidence is expected to increase as the population ages.

The symptoms of AML are caused by replacement of normal bone marrow with leukemic cells, which causes a drop in red blood cells, platelets, and normal white blood cells. These symptoms include fatigue, shortness of breath, easy bruising and bleeding, and increased risk of infection. Several risk factors and chromosomal abnormalities have been identified, but the specific cause is not clear. As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.

AML has several subtypes; treatment and prognosis varies among subtypes. Five-year survival varies from 15–70%, and relapse rate varies from 33-78%, depending on subtype. AML is treated initially with chemotherapy aimed at inducing a remission; patients may go on to receive additional chemotherapy or a hematopoietic stem cell transplant. Recent research into the genetics of AML has resulted in the availability of tests that can predict which drug or drugs may work best for a particular patient, as well as how long that patient is likely to survive.

This text uses material from Wikipedia licensed under CC BY-SA